Journal of Clinical Oncology

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.

Journal of Clinical Oncology

Tracy Batchelor, Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Lakshmi Nayak, John Paul Leonard, James L. Rubenstein

Investigating macrophage function as a mechanism of resistance to daratumumab in relapsed refractory multiple myeloma patients.

Journal of Clinical Oncology

Swetha Kambhampati, Kwun Wah Wen, Victoria Sung, Sandy Wai Kuan Wong, Thomas G. Martin, Jeffrey Lee Wolf, Nina Shah, Arun Wiita

Phase I prospective trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases.

Journal of Clinical Oncology

Nicholas Fidelman, Chloe Evelyn Atreya, Madeline J Griffith, Marion Alexandra Milloy, Julia C. Carnevale, Pelin Cinar, Alan P. Venook, Katherine Van Loon

Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.

Journal of Clinical Oncology

Lauren K. Meyer, Cristina Delgado-Martin, Ritu Roy, Benjamin J. Huang, Tiffaney Vincent, Adam Olshen, Brent L. Wood, Yu Liu, Jinghui Zhang, Charles Grenfell Mullighan, Terzah M. Horton, Mignon L. Loh, Meenakshi Devidas, Elizabeth A. Raetz, Robert J. Hayashi, Stuart Winter, Kimberly P. Dunsmore, Stephen Hunger, David T. Teachey, Michelle L. Hermiston

A regulatory program that promotes metastasis in colorectal cancer (CRC) through modulation of mRNA stability.

Journal of Clinical Oncology

Hani Goodarzi, Robert S. Warren, Johnny Yu, Lisa Fish

A regulatory program that promotes metastasis in colorectal cancer (CRC) through modulation of mRNA stability.

Journal of Clinical Oncology

Hani Goodarzi,Robert S. Warren,Johnny Yu,Lisa Fish

Referral patterns and attrition rate for germline testing in pancreatic cancer (PC) patients.

Journal of Clinical Oncology

Evan Justin Walker, Julia C. Carnevale, Christina Pedley, Amie Blanco, Salina Chan, Eric Andrew Collisson, Andrew H. Ko

Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3 -ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.

Journal of Clinical Oncology

Mark J. Levis, Catherine Choy Smith, Koji Ishizuka, Ken Kobayashi, Meena Arunachalam, Yibin Wang, Deborah Lazzaretto, Jorge E. Cortes

Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.

Journal of Clinical Oncology

Ben Buelow, Priya Choudry, Starlynn Clarke, Kevin Dang, Laura Davison, Shelley Force Aldred, Katherine Harris, Payal Pratap, Duy Pham, Udaya Rangaswamy, Ute Schellenberger, Nina Shah, Nathan Trinklein, Harshad Ugamraj, Arun Wiita, Wim Van Schooten

Development of a fully human t-cell engaging bispecific antibody for the treatment of multiple myeloma.

Journal of Clinical Oncology

Ben Buelow, Priya Choudhry, Starlynn Clarke, Kevin Dang, Laura Davison, Shelley Force Aldred, Katherine Harris, Duy Pham, Payal Pratap, Udaya Rangaswamy, Ute Schellenberger, Nina Shah, Nathan Trinklein, Harshad Ugamraj, Arun Wiita, Wim Van Schooten

Pages